Premium
Influenza vaccine efficacy in young children attending childcare: A randomised controlled trial
Author(s) -
LiKimMoy Jean P,
Yin Jiehui K,
Heron Leon,
Leask Julie,
Lambert Stephen B,
Nissen Michael,
Sloots Theo,
Booy Robert
Publication year - 2017
Publication title -
journal of paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 76
eISSN - 1440-1754
pISSN - 1034-4810
DOI - 10.1111/jpc.13313
Subject(s) - medicine , vaccination , influenza vaccine , adverse effect , pediatrics , trivalent influenza vaccine , randomized controlled trial , vaccine efficacy , live attenuated influenza vaccine , immunology
Aim Influenza causes a substantial burden in young children. Vaccine efficacy ( VE ) data are limited in this age group. We examined trivalent influenza vaccine ( TIV ) efficacy and safety in young children attending childcare. Methods A double‐blind, randomised controlled trial in children aged 6 to <48 months was conducted with recruitment from Sydney childcare centres in 2011. Children were randomised to receive two doses of TIV or control hepatitis A vaccine. Efficacy was evaluated against polymerase chain reaction‐confirmed influenza using parent‐collected nose/throat swabs during influenza‐like‐illness. Safety outcomes were assessed during 6 months of follow‐up. Results Fifty‐seven children were allocated to influenza vaccine and 67 to control; all completed the study. The influenza attack rate was 1.8 vs 13.4% in the TIV and control groups, respectively; VE 87% (95% CI : 0–98%). For children aged 24 to <48 months, 0 vs 8 (18.6%) influenza infections occurred in the TIV and control groups respectively, giving a VE of 100% (16–100%). Efficacy was not shown in children 6 to <24 months, probably due to insufficient power. Injection site and systemic adverse events were mostly mild to moderate with no significant differences, apart from more mild diarrhoea following dose 2 in TIV recipients (11.8 vs 0%). Conclusions Influenza vaccine appeared efficacious in the subgroup of children aged 24 to <48 months, although caution is required due to the small number of participants. There were no serious adverse events and most parents would vaccinate again. Influenza vaccination in a childcare setting could be valuable and a larger confirmatory study would be helpful.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom